Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 5NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 4Unspecified Childhood Solid Tumor, Protocol Specific 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Leukemia 1Congenital Abnormalities 1Breast Neoplasms, Male 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Melphalan 20Cyclophosphamide 17Dexamethasone 14Peripheral Blood Stem Cell Transplantation 12Filgrastim 9sargramostim 8fludarabine phosphate 7Interferon-alpha 7Busulfan 7Bortezomib 7Vincristine 6Thalidomide 6Prednisone 6Doxorubicin 5Antilymphocyte Serum 5Radiotherapy 4Cyclosporine 4Mycophenolic Acid 3Methylprednisolone 3Idarubicin 3Etoposide 3Drug Therapy 3Ascorbic Acid 3Arsenic Trioxide 3Rituximab 2Methotrexate 2Interleukin-12 Subunit p35 2Ifosfamide 2Cytarabine 2Carmustine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasms, Plasma Cell × Immunologic Techniques × Clear all
NCT00742404 2013-12-18

Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

National Cancer Institute (NCI)

Phase 2 Unknown
35 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡